IP Library Granted Patent US 11,806,555
Granted Patent B2
US 11,806,555 · App. 17/868,078 · Granted Nov 7, 2023

Methods for treating hair loss disorders

Inventors: Angela M. Christiano (Mahwah, NJ); Raphael Clynes (West Nyack, NY)
Assignee: The Trustees of Columbia University in the City of New York
A61Q7/00A61K8/41A61K8/4953A61K8/64A61K31/137A61K31/277A61K31/407A61K31/437A61K31/506A61K31/519A61K31/52A61K31/529A61K31/5377A61K31/553A61K31/63A61K31/7052A61K31/713A61K2800/782
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,806,555
App. No.
17/868,078
Granted
Nov 7, 2023
Kind
B2
Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Claims (25)

1. A method of treating alopecia areata in a human subject in need thereof comprising orally administering to the human subject once daily a therapeutically effective amount of LY3009104 to treat alopecia areata in the human subject.

2. The method of claim 1 , wherein the alopecia areata is in patches.

3. The method of claim 1 , wherein the alopecia areata is alopecia totalis.

4. The method of claim 1 , wherein the alopecia areata is alopecia universalis.

5. The method of claim 1 , wherein the LY3009104 is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

6. The method of claim 1 , wherein the alopecia areata is severe alopecia areata.

7. The method of claim 6 , wherein the severe alopecia areata is in patches.

8. The method of claim 6 , wherein the severe alopecia areata is alopecia totalis.

9. The method of claim 6 , wherein the severe alopecia areata is alopecia universalis.

10. The method of claim 6 , wherein LY3009104 is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

11. A method of treating alopecia areata in a human subject in need thereof comprising orally administering to the human subject a therapeutically effective amount of LY3009104 to treat alopecia areata in the human subject.

12. The method of claim 11 , wherein the alopecia areata is in patches.

13. The method of claim 11 , wherein the alopecia areata is alopecia totalis.

14. The method of claim 11 , wherein the alopecia areata is alopecia universalis.

15. The method of claim 11 , wherein LY3009104 is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

16. The method of claim 11 , wherein the alopecia areata is severe alopecia areata.

17. The method of claim 16 , wherein the severe alopecia areata is in patches.

18. The method of claim 16 , wherein the severe alopecia areata is alopecia totalis.

19. The method of claim 16 , wherein the severe alopecia areata is alopecia universalis.

20. The method of claim 16 , wherein LY3009104 is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

21. A method of treating severe alopecia areata in a human subject in need thereof comprising orally administering to the human subject once daily a therapeutically effective amount of LY3009104 to treat severe alopecia areata in the human subject, wherein LY3009104 is the only therapeutically effective agent being administered to the human subject for treating severe alopecia areata.

22. The method of claim 21 , wherein the severe alopecia areata is in patches.

23. The method of claim 21 , wherein the severe alopecia areata is alopecia totalis.

24. The method of claim 21 , wherein the severe alopecia areata is alopecia universalis.

25. The method of claim 21 , wherein the LY3009104 is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Continuity (11)
Continuation 17714964 · Apr 6, 2022
Continuation 16299382 · Mar 12, 2019
Continuation 15668814 · Aug 4, 2017
Continuation 14821623 · Aug 7, 2015
Continuation 13886252 · May 2, 2013
Continuation In Part PCTUS2013034688 · Mar 29, 2013
Continuation In Part PCTUS2011059029 · Nov 2, 2011
Provisional Application 61645499 · May 10, 2012
Provisional Application 61617225 · Mar 29, 2012
Provisional Application 61409509 · Nov 2, 2010
Related Publication 20230043374A1 · Feb 9, 2023
Cited By (1)
US 12,361,556